BillionToOne

We’re proud to share that our Co-Founder and CEO, Oguzhan Atay, PhD, has been selected as a Top Healthcare Technology CEO by The Healthcare Technology Report 🏆 This list celebrates the professionals driving innovation in our industry and their remarkable accomplishments. We're honored by this recognition and grateful to The Healthcare Technology Report for highlighting this important work. Check out the full list here: https://lnkd.in/gc53-idx

So proud to see our CPO, Shan Riku, recognized as one of DeciBio’s Top 20 Women of Precision Medicine (2026) 🎉 Shan’s leadership continues to drive meaningful innovation at BillionToOne, and we are incredibly lucky to have her leading the team.

We’re excited to announce a collaboration with Epic Aura to integrate BillionToOne’s prenatal and oncology testing, including UNITY Complete®, Northstar Select®, and Northstar Response®, into Epic’s Aura diagnostics suite. This integration is focused on simplifying clinical workflows and making advanced molecular diagnostics easier to access and use in everyday care, helping providers deliver more informed care to more patients across both prenatal and oncology settings. Learn more about the collaboration: https://lnkd.in/e8mWGQm2

Yesterday, our CEO, Oguzhan Atay, PhD presented to a packed room at the J.P. Morgan Healthcare Conference on the topic of, "Redefining Molecular Diagnostics with Single-Molecule Precision". Thank you to all who attended! The webcast of the presentation is available to watch here: https://lnkd.in/ePNkw8Gs

We're proud to share our 2026 guidance: $415-430M in revenue, representing 40-45% growth, with continued positive GAAP operating income. This milestone reflects our commitment to solving meaningful clinical challenges through innovative science and dedicated execution. From ultra-sensitive prenatal testing to advanced cancer diagnostics, we're building a platform that makes powerful, accurate diagnostics accessible to all. We're excited for what's ahead in this new year. Read the full announcement: https://lnkd.in/eNFTWtRE

We're thrilled to be at the J.P. Morgan Healthcare Conference in San Francisco, where our management team will present on Monday, January 12th from 9:45-10:25am PT. Join our live webcast to hear updates on what we're doing to provide more intelligent healthcare for all with single molecule diagnostics. More details: https://lnkd.in/eMrJTC4m

A huge thank you to Onyx for featuring our CEO, Oguzhan Atay, PhD, in its CEO feature series for The Onyx Life Sciences Report, which is also being published in Fortune in 2026. In the interview, Dr. Atay shares what led him to found BillionToOne, highlights the company’s fast‑growing list of milestones, and explains how, by “approaching biological problems from physics‑based principles,” BillionToOne is driving rapid, long‑term growth as it pursues groundbreaking innovation in ultra‑sensitive cancer and prenatal testing. You can read the full feature here: https://lnkd.in/eKJJukBp

Happy Holidays from BillionToOne! This year has been one for the books! From celebrating the strength of our team, the trust from our providers and patients, and a major milestone as BillionToOne became a publicly traded company. We’re proud of what we’ve built together and energized by what’s ahead as we continue advancing precision diagnostics and equitable care. Wishing you and your families a happy, healthy holiday season and a bright year ahead.

We are pleased to announce that Anthony Pagano has joined BillionToOne’s Board of Directors as Audit Committee Chair. He brings extensive financial and operational expertise that will support our next phase of growth as a public company. Read the full announcement:    https://lnkd.in/e3AdhkhM

Today, we released our Q3 2025 financial results, reflecting continued momentum across our prenatal and oncology businesses with 117% revenue growth compared to Q3 2024. The results also include full-year revenue guidance of $293–$299 million, representing an estimated 93–96% growth for 2025. Read the full update: https://lnkd.in/e_aGF7_4